InvestorsHub Logo
Followers 828
Posts 119585
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Thursday, 04/27/2017 9:36:44 AM

Thursday, April 27, 2017 9:36:44 AM

Post# of 6095
Lorlatinib gets BTD for ALK+ NSCLC:

http://finance.yahoo.com/news/pfizer-next-generation-alk-ros1-120000233.html

Lorlatinib inhibits ALK and ROS1.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PFE News